ContractThe Exclusive License Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations • Washington
This amendment corrects a technical error where the reference to Section 4.4 as set forth below was incorrectly 4.2 in the original document.
FIRST AMENDMENT TO THE LICENSE AGREEMENT BETWEEN THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS AND QUARK BIOTECHNOLOGY, INC.The Exclusive License Agreement • November 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (the “First Amendment”) is made and entered into as of March 23, 2007 (“Amendment Date”) by and between THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, a body corporate and politic of the State of Illinois, 1737 W. Polk St., Chicago, IL 60612 (“UNIVERSITY”) and QUARK BIOTECH, INC a California corporation, with a principal place of business at 6536 Kaiser Drive, Fremont, CA 94555 (“LICENSEE”).
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • May 5th, 2009 • Alphatec Holdings, Inc. • Surgical & medical instruments & apparatus
This First Amendment to the Exclusive License Agreement (this “Amendment”) is made effective as of March 31, 2009 (the “Effective Date”) between Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Licensee”) and Stout Medical Group LP, a limited partnership company organized under the laws of the state of Delaware, and having a place of business at 410 East Walnut Street, Suite #8, Perkasie, Pennsylvania 18944 (“Licensor”). Licensee and Licensor are each hereafter referred to individually as a “Party” and together as the “Parties”.
AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • October 8th, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations
This first amendment (“Amendment”) to the Amended and Restated Exclusive License Agreement between The Arizona Board of Regents on behalf of The University of Arizona, with its principal offices in Tucson, Arizona 85721 ("ARIZONA") and Cancer Prevention Pharmaceuticals, Inc. an Delaware Corporation with its principal place of business at 1760 E. River Rd., Suite 250, Tucson, AZ 85718 ("LICENSEE") is made effective on the date of the last authorized signature below (“Amendment Effective Date”).
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIESThe Exclusive License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 23rd, 2003 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at Two Corporate Drive, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland, California 94607-5300, acting through its Office of Technology Licensing at the University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • November 2nd, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the Exclusive License Agreement (“Second Amendment”) effective as of August 3, 2021 (“Second Amendment Effective Date”) is by and between: Eisai inc., with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and Allarity Therapeutics A/S, with its principal office at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”) (formerly known as Oncology Venture ApS), with reference to the following:
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • December 18th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
This Third Amendment to the Exclusive License Agreement (the “Third Amendment”) is made and entered into this 9 th day of April 2019 (the “Third Amendment Effective Date”) by and between the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver at the Anschutz Medical Campus (“University”), and AdMiRx, Inc. a Delaware corporation (“Licensee”).
Third Amendment to Exclusive License Agreement for Selected Applications of Coated Nanocrystalline Particles between The Regents of the University of California and BioSante Pharmaceuticals, Inc. UC Case No. 1989-204The Exclusive License Agreement • August 16th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This third amendment (“Third Amendment”) is effective this 30th of June, 2004, by and between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and BioSante Pharmaceuticals, Inc. (“Licensee”), a Delaware corporation, having a principal place of business at 111 Barclay Boulevard, Lincolnshire, IL 60069.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIESThe Exclusive License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 15, 2002 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at 270 Littlefield Avenue, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland, California 94607-5300, acting through its Office of Technology Licensing at the University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • February 3rd, 2006 • Quatrx Pharmaceuticals Co
AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • March 29th, 2019 • Clementia Pharmaceuticals Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to the Exclusive License Agreement dated March 29, 2017 (the “Agreement”), is executed as of 07 December, 2018 (the “Amendment Effective Date”), by and between Galderma Research & Development SNC, a société en nom collectif organized under the laws of France having its principal address at Les Templiers, 2400 route des Colles, 06410 Biot, France (“Galderma”), and Clementia Pharmaceuticals Inc., a corporation organized under the federal laws of Canada having its principal address of 4150 Saint Catherine West, Suite 550, Montreal, Quebec, Canada H3Z2Y5 (“Clementia”). Each of Galderma and Clementia is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations
This AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of October 8, 2020 (the “Amendment Effective Date”), is entered into by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Licensing, LLC, a limited liability company organized and existing under the laws of the State of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and MyoKardia, Inc., a corporation organized and existing under the laws of the State of Delaware, United States (“Company”). LianBio, Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations
This THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of December 17, 2020 (the “Amendment Effective Date”), is entered into by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Licensing, LLC, a limited liability company organized and existing under the laws of the State of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.), a Delaware corporation (“Company”). LianBio, Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of December 14, 2021 (the “Amendment Effective Date”), is entered into by and between Lian Oncology Limited, a limited company incorporated under the laws of Hong Kong (“Lian Oncology HK”), LianBio Licensing, LLC, a Delaware limited liability company and an Affiliate of LianBio (“LianBio Licensing”), Lian Oncology, an exempted company organized under the laws of the Cayman Islands (“Lian Oncology”) (together, “Licensee”), and QED Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”). Licensee and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE...The Exclusive License Agreement • February 29th, 2024 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) is made effective May 21, 2021 (the “First Amendment’s Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at [***] (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at [***], and Sana Biotechnology, Inc. (“Licensee”), a Delaware Corporation having its principal place of business at 188 E. Blaine St., Suite 400, Seattle WA 98102, and amends the license agreement with Licensee, dated March 01, 2019 with UC Agreement Control Number [***] (the “Agreement”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • December 18th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
This Second Amendment to the Exclusive License Agreement (the “Second Amendment”) is made and entered into this 27th day of September 2018 (the “Second Amendment Effective Date”) by and between the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver at the Anschutz Medical Campus (“University”), and AdMiRx, Inc. a Delaware corporation (“Licensee”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations
This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of January 4, 2021 (the “Amendment Effective Date”), is entered into by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Licensing, LLC, a limited liability company organized and existing under the laws of the State of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and MyoKardia, Inc., a corporation organized and existing under the laws of the State of Delaware, United States (“Company”). LianBio, Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations
This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of September 28, 2020 (the “Amendment Effective Date”), is entered into by and among LianBio, a corporation organized and existing under the laws of the Cayman Islands (“LianBio”), LianBio Licensing LLC, a limited liability company organized and existing under the laws of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.), a Delaware corporation (“Company”). LianBio, Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • December 18th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
This First Amendment to the Exclusive License Agreement (the “First Amendment”) is made and entered into this 8th day of February 2018 (“First Amendment Effective Date”) by and between the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver (“University”), and AdMiRx, Inc. a Delaware corporation (“Licensee”).
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT NO. 5 TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • February 27th, 2014 • OvaScience, Inc. • Pharmaceutical preparations
This Amendment No. 5 (this “Amendment”) to the Exclusive License Agreement between OvaScience, Inc. (“Company”) and The General Hospital Corporation (“Hospital”), dated June 27, 2011 (the “Agreement”), is effective upon signing by both parties hereto. Capitalized terms used but not defined within this Amendment have the meanings specified within the Agreement.
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT DATED JANUARY 31, 1995 between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CYGNUS, INC. for DEVICE FOR IONTOPHORETIC NON-INVASIVE SAMPLING OR DELIVERY OF SUBSTANCES UC Agreement Control Number...The Exclusive License Agreement • February 20th, 2003 • Cygnus Inc /De/ • Measuring & controlling devices, nec
This second amendment, (“Second Amendment”) is effective this 19th day of September, 2002 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), and Cygnus, Inc., a Delaware corporation having its principal place of business at 400 Penobscot Drive, Redwood City, California 94063, formerly known as Cygnus Therapeutic Systems, a California corporation (“Licensee”).
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • June 14th, 2019 • Histogenics Corp • Orthopedic, prosthetic & surgical appliances & supplies • Colorado
This First Amendment to the Exclusive License Agreement (the “First Amendment”) is made and entered into this 23rd day of January, 2017 (“First Amendment Effective Date”) by and between the Regents of the University of Colorado, a body corporate, having its principal office at 1800 Grant Street, 8th Floor, Denver, CO 80203 (“University”), and Ocugen, Inc., a Delaware company having its principal office at Bioscience Park Center, 12635 E. Montview Blvd, Suite 100, Aurora, CO 80045 (“Licensee”).
THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTThe Exclusive License Agreement • October 30th, 2014 • Alphatec Holdings, Inc. • Surgical & medical instruments & apparatus
This Third Amendment to the Exclusive License Agreement (this “Amendment”) is made effective as of August 1, 2014 (the “Amendment No. 3 Effective Date”) between Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 5818 El Camino Real, Carlsbad, California 92008 (“Licensee”) and Stout Medical Group LP, a limited partnership company organized under the laws of the state of Delaware, and having a place of business at 101 E. Mill Street, Unit P, Quakertown, Pennsylvania 18951 (“Licensor”). Licensee and Licensor are each hereafter referred to individually as a “Party” and together as the “Parties”.
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT DATED JANUARY 31, 1995 between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CYGNUS, INC. for DEVICE FOR IONTOPHORETIC NON-INVASIVE SAMPLING OR DELIVERY OF SUBSTANCES UC Agreement Control Number...The Exclusive License Agreement • April 21st, 2003 • Cygnus Inc /De/ • Measuring & controlling devices, nec
This second amendment, (“Second Amendment”) is effective this 19th day of September, 2002 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), and Cygnus, Inc., a Delaware corporation having its principal place of business at 400 Penobscot Drive, Redwood City, California 94063, formerly known as Cygnus Therapeutic Systems, a California corporation (“Licensee”).
INFORMATION IN THIS EXHIBIT IDENTIFIED BY BRACKETS IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CASI PHARMACEUTICALS, INC. IF...The Exclusive License Agreement • November 9th, 2020 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Hong Kong
This Supplementary Agreement to the Exclusive License Agreement (this “Agreement”), is entered into as of September 29, 2020 (Beijing Time, “Effective Date”), by and between:
INSIDE INFORMATION Exclusive license agreement with Tencent and KoramThe Exclusive License Agreement • September 2nd, 2014
This announcement is made by Feiyu Technology International Company Ltd. (the “Company” and, together with its subsidiaries, the “Group”) pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.
